News | Prostate Cancer | July 02, 2024

The deployment of DL segmentation methods in 18F-fluciclovine PET/CT imaging represents an intriguing research direction for precision medicine in salvage prostate cancer care

The deployment of DL segmentation methods in 18F-fluciclovine PET/CT imaging represents an intriguing research direction for precision medicine in salvage prostate cancer care

July 2, 2024 — A new editorial paper was published in Oncoscience (Volume 11) on May 20, 2024, entitled, “Deep learning-assisted lesion segmentation in PET/CT imaging: A feasibility study for salvage radiation therapy in prostate cancer.”

In this new editorial, researchers Richard L.J. Qiu, Chih-Wei Chang, and Xiaofeng Yang from Emory University discuss prostate cancer. Prostate cancer persists as the most frequently diagnosed malignancy in men beyond skin cancer. Despite substantial advancements in treatment outcomes over the past half century, progression or recurrence post-initial treatments like prostatectomy or radiation therapy remains a challenge for a subset of patients. 

“In those scenarios, salvage radiation therapy is often offered to patients as a treatment option. To design the salvage radiation therapy, imaging is required to detect and locate the recurrence disease regime.” 

Traditional imaging modalities employed post-prostatectomy, such as CT, bone scans, MRI or 18F-FDG PET, often fall short in accurately detecting and determining the volume of the recurrent disease, which is crucial for salvage radiation treatment planning. However, the introduction of 18F-fluciclovine (anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid) PET/CT has marked a significant advancement in salvage disease management. Recent studies, including the phase 2/3 randomized controlled trial, Emory Molecular Prostate Imaging for Radiotherapy Enhancement (EMPIRE-1), demonstrated improved biochemical recurrence or persistence free survival rates when incorporating 18F-fluciclovine PET/CT into post-prostatectomy radiation therapy planning.

One key step in salvage radiation therapy planning is the delineation of lesions on the 18F-fluciclovine PET/CT images, a task currently undertaken manually by physicians. This practice, while meticulous, is labor-intensive and prone to inter- and intra-observer variations. With the recent explosion of using artificial intelligence (AI) algorithms in medical image processing, automatic segmentation of lesions using deep learning (DL)-based lesion delineation methods demonstrate promising potential to improve treatment quality, as opposed to manual contouring. 

For more information: https://www.oncoscience.us/


Related Content

News

Aug. 5, 2024 — Researchers from The University of Texas MD Anderson Cancer Center have demonstrated that adding ...

Time August 09, 2024
arrow
News | PET-CT

July 31, 2024 — In a head-to-head comparison with FDG PET/CT, FDG PET/MRI demonstrated comparable or superior diagnostic ...

Time July 31, 2024
arrow
Feature | Radiation Oncology | By Christine Book

News emerging from several leading organizations and vendors in the radiation therapy arena came in at a fast pace in ...

Time July 30, 2024
arrow
News | Prostate Cancer

July 30, 2024 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization ...

Time July 30, 2024
arrow
News | Radiology Business

July 25, 2024 — Immunis, Inc., a clinical-stage biotech developing groundbreaking secretome therapeutics for age and ...

Time July 25, 2024
arrow
News | Radiopharmaceuticals and Tracers

July 25, 2024 — NorthStar Medical Radioisotopes, LLC and BWXT Medical Ltd., a subsidiary of BWX Technologies, Inc ...

Time July 25, 2024
arrow
News | Radiopharmaceuticals and Tracers

July 24, 2024 — Telix Pharmaceuticals Limited announced that the United States (U.S.) Food and Drug Administration (FDA) ...

Time July 24, 2024
arrow
News | RSNA

July 23, 2024 — Professional registration is open for RSNA 2024, the world’s largest radiology forum. This year’s theme ...

Time July 23, 2024
arrow
News | Artificial Intelligence

July 23, 2024 — Researchers at the National Institutes of Health (NIH) found that an artificial intelligence (AI) model ...

Time July 23, 2024
arrow
News | Artificial Intelligence

July 17, 2024 — Hyperfine, a groundbreaking medical device company that has redefined brain imaging with the world’s ...

Time July 17, 2024
arrow
Subscribe Now